Abstract
Relying on previous regulatory guidelines from multiple countries, the ICH S5(R2) guideline outlines the preclinical safety studies needed for registration of new medicinal products in the member countries (European Union, Japan, and the United States). The primary purpose of the guideline is to provide a testing strategy to detect and reveal toxicity to the reproductive system including development of the embryo. There are basically three study designs outlined by the guidance, assessment of fertility in adults, pre- and postnatal development of exposed offspring, and morphological evaluation following exposure during major organogenesis. This chapter discusses the major points addressed in the guidance for each study type, and points to additional references that discuss the practical details for conducting such studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Christian MS, Hoberman AM, Lewis EM (2006) Perspectives on the developmental and reproductive toxicity guidelines. In: Hood RD (ed) Developmental and reproductive toxicology, a practical approach. CRC, Boca Raton, pp 733–798
Barrow PC (2009) Reproductive toxicity testing for pharmaceuticals under ICH. Reprod Toxicol 28:172–179
Lankas GR, Cukierski MA, Wise LD (2004) The role of maternal toxicity in lovastatin-induced developmental toxicity. Birth Defects Res B Dev Reprod Toxicol 71:111–123
Lerman SA, Hew KW, Stewart J, Stump DG, Wise LD (2009) The nonclinical fertility study design for pharmaceuticals. Birth Defects Res B Dev Reprod Toxicol 86:429–436
Bailey GP, Wise LD, Buschmann J, Hurtt M, Fisher JE (2009) Pre- and postnatal developmental toxicity study design for pharmaceuticals. Birth Defects Res B Dev Reprod Toxicol 86:437–445
Wise LD, Buschmann J, Feuston MH, Fisher JE, Hew KW, Hoberman AM, Lerman SA, Ooshima Y, Stump DG (2009) Embryo-fetal developmental toxicity study design for pharmaceuticals. Birth Defects Res B Dev Reprod Toxicol 86:418–428
Chen JJ (2006) Statistical analyses for developmental and reproductive toxicologists. In: Hood RD (ed) Developmental and reproductive toxicology, a practical approach. CRC, Boca Raton, pp 697–711
Chahoud I, Buschmann J, Clark R, Druga A, Falke H, Faqi A, Hansen E, Heinrich-Hirsch B, Hellwig J, Lingk W, Parkinson M, Paumgartten FJ, Pfeil R, Platzek T, Scialli AR, Seed J, Stahlmann R, Ulbrich B, Wu X, Yasuda M, Younes M, Solecki R (1999) Classification terms in developmental toxicology: need for harmonisation. Report of the Second Workshop on the Terminology in Developmental Toxicology. Berlin, 27–28 August 1998. Reprod Toxicol 13:77–82
Wise LD, Beck SL, Beltrame D, Beyer BK, Chahoud I, Clark RL, Clark R, Druga AM, Feuston MH, Guittin P, Henwood SM, Kimmel CA, Lindstrom P, Palmer AK, Petrere JA, Solomon HM, Yasuda M, York RG (1997) Terminology of developmental abnormalities in common laboratory mammals (Version 1). Teratology 55:249–292
Makris SL, Solomon HM, Clark R, Shiota K, Barbellion S, Buschmann J, Ema M, Fujiwara M, Grote K, Hazelden KP, Hew KW, Horimoto M, Ooshima Y, Parkinson M, Wise LD (2009) Terminology of developmental abnormalities in common laboratory mammals (Version 2). Birth Defects Res B Dev Reprod Toxicol 86:227–327
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Wise, L.D. (2013). The ICH S5(R2) Guideline for the Testing of Medicinal Agents. In: Barrow, P. (eds) Teratogenicity Testing. Methods in Molecular Biology, vol 947. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-131-8_1
Download citation
DOI: https://doi.org/10.1007/978-1-62703-131-8_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-130-1
Online ISBN: 978-1-62703-131-8
eBook Packages: Springer Protocols